Vir Biotechnology's coronavirus treatment is losing steam. The company's pipeline looks somewhat promising on first glance. But the biotech's most recent data readout was not encouraging. This could ...

ALTON, Va. (WFXR) – The VIRginia International Raceway (VIR) has announced this year is its 25th anniversary and is gearing up to celebrate with high-octane heart-pumping thrills all season.

Updated Phase 1 dose-escalation data (n=58) show VIR-5500 monotherapy has a favorable safety profile and was well tolerated with no dose-limiting toxicities observed to date - Dose-dependent anti-tumo ...

Vir Biotechnology said Thursday that a long-acting antibody drug designed to protect healthy individuals from influenza A failed to do so in a nearly 3,000-person clinical trial. Volunteers who ...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Timothy Coughlin to its Board of Directors and as Chair of the Audit Committee, effective June 9, 2026. “We are pleased to ...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024. “This quarter was ...

UKRAINE - 2022/01/23: In this photo illustration, a Vir Biotechnology logo is seen on a smartphone and a computer screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images) ...

Despite interest from GSK and high hopes of leading the next generation of influenza A prophylaxis, Vir Biotechnology’s monoclonal antibody has failed its first phase 2 challenge. The PENINSULA study ...

– Conference call scheduled for February 23, 2026, at 5:30 p.m. ET / 2:30 p.m. PT SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported ...

Vir Biotechnology is rated a buy, supported by a strong cash position, pivotal late-stage pipeline, and deep institutional backing. VIR's lead CHD drugs, Tobevibart and Elebsiran, target a large, ...